OGNOGN

Psychiatry40 cited findings · profile updated 2026-08-26

About OGN

OGN is a company focused on psychiatry. Their drug Sycrest (asenapine) received a positive opinion from the CHMP for granting of the marketing authorisation in bipolar I disorder. The recommended dose range for Sycrest is 5 mg to 10 mg twice daily. Asenapine demonstrates high affinity and antagonism at various receptors, including 5-HT2C receptors (pKi 10.5, pKB 9.0) and D2 receptors (pKB 9.1). The bioavailability of Sycrest after sublingual dosing is approximately 35%, while after oral dosing it is <2%.

Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.

Key figures — cited

CHMP recommendation for Sycrest in bipolar I disorder	granting of the marketing authorisation	Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.88
Sycrest (asenapine) recommended dose range	5 mg to 10 mg twice daily	Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.5
Sycrest (asenapine) bioavailability after sublingual dosing	approximately 35%	Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.6
Sycrest (asenapine) bioavailability after oral dosing	<2%	Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.6
Asenapine affinity for 5-HT2C receptors	10.5 (pKi)	Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.11
Asenapine antagonism at D2 receptors	9.1 (pKB)	Organon & Co. — Sycrest EMA EPAR public assessment report (EMEA/H/C/00, p.11

Key projects

Sycrest (asenapine) (bipolar I disorder) — EU
The CHMP recommended the granting of the marketing authorisation for Sycrest in bipolar I disorder.
Exxua (gepirone) — Global
The original NDA submission date for Exxua (gepirone) was September 30, 1999.

Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Psychiatry research library →